Company: DVAX
Filing Date: 2025-03-10
Form Type: DFAN14A
Source: 0001193125-25-050430
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-03-10
Form: DFAN14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting material Pursuant to §240.14a-12 |

Dynavax Technologies Corporation (Name of Registrant as Specified In Its Charter) DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP TRACK CAPITAL, LP DAVID KROIN BRETT A. ERKMAN JEFFREY S. FARROW MICHAEL MULLETTE DONALD J. SANTEL (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. |

Deep Track Capital, LP a Delaware limited partnership (“Deep Track”), together with the other participants named herein (collectively the “Participants”), issued the following press release and letter to the Board of Directors (collectively the “Materials”) related to Dynavax Technologies Corporation, a Delaware corporation (the “Company”). Deep Track or its fellow Participants may disseminate the Materials from time to time. Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors Notes Investor Feedback Supporting Deep Track’s Course of Action and Sharing Concerns with Company’s Capital Allocation Strategy, Poor Governance, and Lack of Shareholder Perspective in the Boardroom Highlights Dynavax’s Refusal to Reach a Constructive Resolution and Calls on Board to Stop Engaging in Petty “Activism Defense 101” Tactics Questions Company’s Issuance of Expensive Convertible Notes in Recent Refinancing Instead of Using Cash on Hand Sets Record Straight Regarding Dynavax’s Misleading Assertion That Deep Track is Seeking Control of the Board – Which is Simply False Reiterates Need for a